CSafe Global launches real-time shipment visibility platform
Industry customers now have access to 24/7 real-time shipment visibility across the company's entire product portfolio
CSafe Global, an innovation provider of temperature-controlled container solutions for pharmaceuticals transformation has announced the full commercial launch of its real-time shipment visibility platform and technology.
Users of CSafe can now make data-driven decisions to ensure the safe delivery of medicines to patients worldwide.
Available now to CSafe air cargo customers, the company has already started retrofitting active RKN and RAP containers with the new sensors capable of tracking location and condition.
The platform, custom built by Cloudleaf in close collaboration with CSafe operations, provides real-time alerts and notifications directly to customers via email, text or in the platform itself of the following for each shipment: cargo temperature outside set parameters, door open events, ambient temperature change outside set parameters, shock event, tilt event, ambient pressure change outside set parameters, ambient humidity change outside set parameters and route deviation/delay.
The new platform will also benefit customers with its range of other additional features; for example, they will have access to historical shipments, be able to add unlimited platform users and receive GDP-compliant standard shipment reports.
Describing the culmination of the 2-year project, Patrick Schafer, CSafe CEO, said the new platform delivers "so much more than just basic functionality". Instead, it is a "system that is fit for our customers’ needs today and agile enough to easily accommodate enhancements and new innovations well into the future," he added.
The work is not yet over. Tom Weir, CSafe COO, said the company will be retrofitting the remainder of the active container fleet throughout Q1 before moving on to enhancements. The company also plans to bring its cell & gene customers onto the platform and implement the system for VIP Parcel containers and customers.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance